Language Selector:

Lungpacer Medical has received FDA Premarket Approval for the AeroPace System

Dedicated to
Natural Breathing

Designed to help patients wean off
a ventilator and breathe on their own

Without a strong diaphragm it is impossible to breathe independently*

Artificial breathing support from a ventilator may weaken the diaphragm muscle more than 50% in less than one day* making it difficult to regain independent breathing.

Lungpacer is designed as a personal trainer for the diaphragm muscle*

Lungpacer’s AeroPace system is designed to stimulate the nerves that activate the diaphragm with repetitive exercises for 10-20 minutes twice per day to rebuild diaphragm strength and empower natural, independent breathing*.

Potential Benefits

Wean off a
ventilator faster*

Minimize
ventilator trauma*

Save
cost and
time*

Greater
chance
of survival*

Better
quality
of life*

Our Vision for the Future of Patient Care

Ventilator

Breathing Complications

Ventilator breathing bypasses the brain and diaphragm by forcing air into the lungs causing damage in less than one day

Lungpacer

Designed to Empower Natural Breathing

Engage the diaphragm, lungs, and brain
to support natural breathing

Diaphragm: Inactive

Causes muscle weakness and inability to wean off ventilator, long term complications and higher risk of death*

Lungs: Unevenly inflated

Causes lung tissue damage and respiratory complications*

Brain: Signal impaired

Causes cell death and cognitive injury*

Diaphragm: Exercised

Strengthen muscle through stimulated contractions to accelerate ventilator weaning*

Lungs: Naturally inflated

Protect lung tissue and improve lung function*

Brain: Signal normalized

Protect cells linked to cognitive decline due to ventilation*

Outcomes from AeroPace Clinical Studies Showed

Using AeroPace Therapy Compared to Standard of Care, More patients weaned:

37 %
Reduced risk of remaining on mechanical ventilation at 30 days by up to 37%*
60 %
Reduced risk for reintubation at 30 days by up to 60%*
3 Days
Faster weaning by nearly 3 days*

The AeroPace System is indicated is to improve weaning success – increase weaning, reduce ventilator days, and reduce reintubation – in patients ages 18 years or older on mechanical ventilation ≥ 96 hours and who have not weaned.  It is the first device of this kind approved by FDA.

The AeroPace System is contraindicated in patients with active implanted cardiac pacemakers, defibrillators, or other implantable electronics within proximity to the device. The AeroPace System has not been clinically evaluated for safety with implantable devices.

Lungpacer therapy provides an exciting potential solution to help mechanically ventilated patients return to natural breathing more quickly.
Dr. Joseph Shrager - Stanford University School of Medicine

Lungpacer Medical Research

10
Scientific Abstracts
& Presentations
5
Peer Reviewed
Publications
10 +
Patients
Studied

Learn more about results and trends from more than seven years of Lungpacer research.

Lungpacer AeroPace System

For patients unable to breathe on their own, the AeroPace therapy is designed to provide repetitive exercises, to rebuild diaphragm muscle strength critical to healthy breathing.

The AeroPace System is indicated to improve weaning success – increase weaning, reduce ventilator days, and reduce reintubation – in patients ages 18 years or older on mechanical ventilation at least 96 hours and who have not weaned.